1
|
Yu CC, Lee AF, Kohl S, Lin MY, Cheng SM, Hung CC, Chang JM, Chiu YW, Hwang SJ, Otto EA, Hildebrandt F, Hwang DY. PKD2 founder mutation is the most common mutation of polycystic kidney disease in Taiwan. NPJ Genom Med 2022; 7:40. [PMID: 35778421 PMCID: PMC9249874 DOI: 10.1038/s41525-022-00309-w] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Accepted: 06/09/2022] [Indexed: 11/09/2022] Open
Abstract
Autosomal Dominant polycystic kidney disease (ADPKD) is the most common inherited adult kidney disease. Although ADPKD is primarily caused by PKD1 and PKD2, the identification of several novel causative genes in recent years has revealed more complex genetic heterogeneity than previously thought. To study the disease-causing mutations of ADPKD, a total of 920 families were collected and their diagnoses were established via clinical and image studies by Taiwan PKD Consortium investigators. Amplicon-based library preparation with next-generation sequencing, variant calling, and bioinformatic analysis was used to identify disease-causing mutations in the cohort. Microsatellite analysis along with genotyping and haplotype analysis was performed in the PKD2 p.Arg803* family members. The age of mutation was calculated to estimate the time at which the mutation occurred or the founder arrived in Taiwan. Disease-causing mutations were identified in 634 families (68.9%) by detection of 364 PKD1, 239 PKD2, 18 PKHD1, 7 GANAB, and 6 ALG8 pathogenic variants. 162 families (17.6%) had likely causative but non-diagnostic variants of unknown significance (VUS). A single PKD2 p.Arg803* mutation was found in 17.8% (164/920) of the cohort in Taiwan. Microsatellite and array analysis showed that 80% of the PKD2 p.Arg803* families shared the same haplotype in a 250 kb region, indicating those families may originate from a common ancestor 300 years ago. Our findings provide a mutation landscape as well as evidence that a founder effect exists and has contributed to a major percentage of the ADPKD population in Taiwan.
Collapse
Affiliation(s)
- Chih-Chuan Yu
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
- Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - An-Fu Lee
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - Stefen Kohl
- Department of Pediatrics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Ming-Yen Lin
- Division of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Siao Muk Cheng
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
| | - Chi-Chih Hung
- Division of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Jer-Ming Chang
- Division of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Yi-Wen Chiu
- Division of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Shang-Jyh Hwang
- Division of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| | | | - Friedhelm Hildebrandt
- Department of Pediatrics, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - Daw-Yang Hwang
- National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan.
- Division of Nephrology, Department of Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Center for Biomarkers and Biotech Drugs, Department of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan.
| |
Collapse
|
2
|
García Rabaneda C, Perea F, Bellido Díaz ML, Morales García AI, Martínez Atienza M, Sousa Silva L, González MÁG, Cabello FR, Esteban de la Rosa RJ. Founding mutations explains hotspots of polycystic kidney disease in Southern Spain. Clin Kidney J 2020; 14:1845-1847. [PMID: 34221391 PMCID: PMC8243269 DOI: 10.1093/ckj/sfaa261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Accepted: 11/23/2020] [Indexed: 11/14/2022] Open
Abstract
Our group identified two pathogenic variants on the PKD1 gene, c.10527_10528delGA and c.7292T>A, from unrelated families. They came from two small counties in Granada, with 61 and 26 autosomal dominant polycystic kidney disease (ADPKD) individuals affected. To determine a common ancestor, healthy and ADPKD individuals from these families were genotyped by analysing four microsatellites located on chromosome 16. Our study identified a common haplotype in all ADPKD individuals. These findings underpin our hypothesis of the founder effect and explain why there is a high frequency of ADPKD in small regions. Determining hotspots of ADPKD will help to better plan healthcare in the future.
Collapse
Affiliation(s)
- Carmen García Rabaneda
- Servicio de Análisis Clínicos, Hospital Universitario San Cecilio, Granada, Spain.,Grupo de Estudio de la Enfermedad Poliquística Autosómica Dominante (GEEPAD), Granada, Spain
| | - Francisco Perea
- Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico, Granada, Spain.,Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio ClÍnico, Granada, Spain
| | - María Luz Bellido Díaz
- Grupo de Estudio de la Enfermedad Poliquística Autosómica Dominante (GEEPAD), Granada, Spain.,Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico, Granada, Spain.,Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio ClÍnico, Granada, Spain
| | - Ana I Morales García
- Grupo de Estudio de la Enfermedad Poliquística Autosómica Dominante (GEEPAD), Granada, Spain.,Servicio de Nefrología, Hospital Universitario San Cecilio, Granada, Spain.,Instituto de Investigación Biosanitario de Granada (IBS.GRANADA), Granada, Spain
| | - Margarita Martínez Atienza
- Grupo de Estudio de la Enfermedad Poliquística Autosómica Dominante (GEEPAD), Granada, Spain.,Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio Clínico, Granada, Spain.,Servicio de Análisis Clínicos e Inmunología, UGC Laboratorio ClÍnico, Granada, Spain
| | - Lisbeth Sousa Silva
- Laboratorio de Genética del Complejo Hospitalario Universitario de Santiago de Compostela (NEFROCHUS) Spain
| | | | | | - Rafael J Esteban de la Rosa
- Grupo de Estudio de la Enfermedad Poliquística Autosómica Dominante (GEEPAD), Granada, Spain.,Instituto de Investigación Biosanitario de Granada (IBS.GRANADA), Granada, Spain.,Servicio de Nefrología, Hospital Universitario Virgen de las Nieves, Granada, Spain.,Asociación Amigos del Riñón, Granada, Spain
| |
Collapse
|